GSK3B and pancreatic neoplasm: The viability of therapeutic targeting of GSK-3β has been demonstrated via pharmacological inhibition and RNA interference to reduce cancer cell survival and proliferation and induce apoptosis in gastrointestinal and pancreatic cancer cells, glioblastoma, hematologic malignancies, osteo-sarcoma, gynaecologic and urogenital cancers, and lung cancers [52,53].